Multiparametric response assessment in patients with metastatic/advanced pulmonary neuroendocrine tumours by using 177Lu-DOTATATE peptide receptor radionuclide therapy

Trial Profile

Multiparametric response assessment in patients with metastatic/advanced pulmonary neuroendocrine tumours by using 177Lu-DOTATATE peptide receptor radionuclide therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Octreotate-Lu-177-DOTA-Tyr-3 (Primary)
  • Indications Neuroendocrine tumours
  • Focus Diagnostic use
  • Most Recent Events

    • 01 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top